The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer

As an antibody-drug conjugate (ADC), disitamab vedotin (RC48) is a promising treatment targeting ERBB2 for locally advanced and metastatic bladder cancer (BLCA). However, the subtype heterogeneity of muscle-invasive bladder cancer (MIBC) often leads to different therapeutic outcomes. In our study, w...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jingxian Li, Kun Shan, Wei Huang, Qiang Su, Yuanjiong Qi, Zhihong Zhang, Jianqiang Zhu, E. Du
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2025-01-01
coleção:	Frontiers in Immunology
Assuntos:	RC48-ADC MIBC artesunate molecular subtypes targeted therapy
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1432586/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!